Tirzepatide vs Survodutide: A Research Comparison
Tirzepatide and Survodutide are both dual receptor agonists studied in metabolic research, and both engage the GLP-1 receptor; the difference is the second receptor. Tirzepatide adds GIP-receptor activity, while Survodutide adds glucagon-receptor activity. Their regulatory status differs sharply: Tirzepatide is an approved drug while Survodutide is investigational. The canonical difference is GIP versus glucagon as the partner receptor. Both are supplied here as research-use-only materials distinct from any approved product.
The core difference: the second receptor
Both compounds are dual agonists that share GLP-1-receptor activity, so the distinction is the partner receptor and what it does metabolically. Tirzepatide engages the GIP (glucose-dependent insulinotropic polypeptide) receptor alongside GLP-1, pairing two incretin signals that both amplify glucose-dependent insulin secretion. Survodutide engages the glucagon receptor alongside GLP-1, pairing an incretin signal with a glucagon signal associated in research with energy expenditure and hepatic lipid handling. The GIP-versus-glucagon axis is the defining distinction.
Structure and molecular profile
Both are large, acylated synthetic peptides engineered for extended stability. Tirzepatide is a 39-residue peptide (molecular weight near 4813.5 g/mol) carrying aminoisobutyric acid substitutions and a fatty-diacid acylation. Survodutide is an acylated peptide (molecular weight near 4231.7 g/mol); exact modification positions should be confirmed against each Certificate of Analysis.
Clinical and regulatory context
The two sit at different regulatory stages. Tirzepatide is approved by the FDA and marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, and has been studied extensively in human clinical trials, including the SURPASS program in type 2 diabetes and the SURMOUNT program in obesity. Survodutide (development code BI 456906) is an investigational dual glucagon/GLP-1 receptor agonist that has been studied in human clinical trials within metabolic and liver-related endpoints, including Phase 2 trials in obesity and in metabolic dysfunction-associated steatohepatitis (MASH), and has not received regulatory approval. Those statements describe regulated or investigational pharmaceutical programs; the Tirzepatide and Survodutide supplied here are research-use-only materials, not those drug products.
How each is studied
Research with Tirzepatide examines glucose-dependent insulin secretion and glucose handling through combined GIP and GLP-1 signaling. Research with Survodutide examines glucagon-receptor contributions to energy expenditure and hepatic metabolism alongside GLP-1 signaling. A protocol chooses between them by which second axis is under study: the incretin GIP axis for Tirzepatide, the glucagon axis for Survodutide.
All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.